Architecture and fiber type of the pyramidalis muscle

بواسطة Lovering, Richard M., Anderson, Larry D.
منشور في 2008

Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma

بواسطة Halm, Ethan A., Anderson, Larry D., Gerber, David E.
الحاوية / القاعدة J Clin Oncol (2017)

Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma

بواسطة Siddiq, Namrah, Bergstrom, Colin, Anderson, Larry D, Nagalla, Srikanth
الحاوية / القاعدة BMJ Case Rep (2019)

Adoptive T-cell therapy for B-cell malignancies

بواسطة Hudecek, Michael, Anderson, Larry D, Nishida, Tetsuya, Riddell, Stanley R
منشور في 2009

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma

بواسطة Anderson, Larry D., Cook, Danielle R., Yamamoto, Tori N., Berger, Carolina, Maloney, David G., Riddell, Stanley R.
منشور في 2011

DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

بواسطة Lambracht-Washington, Doris, Qu, Bao-Xi, Fu, Min, Anderson, Larry D., Stüve, Olaf, Eagar, Todd N., Rosenberg, Roger N.
منشور في 2011

Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect

بواسطة Maffini, Enrico, Anderson, Larry D., Sandmaier, Brenda M., Green, Damian J., Storer, Barry E., Niederwieser, Dietger, Maziarz, Richard T., Maloney, David G., Storb, Rainer
الحاوية / القاعدة Haematologica (2018)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

بواسطة Jagannath, Sundar, Lin, Yi, Goldschmidt, Hartmut, Reece, Donna, Nooka, Ajay, Senin, Alicia, Rodriguez-Otero, Paula, Powles, Ray, Matsue, Kosei, Shah, Nina, Anderson, Larry D., Streetly, Matthew, Wilson, Kimberly, Le, Hoa Van, Swern, Arlene S., Agarwal, Amit, Siegel, David S.
الحاوية / القاعدة Blood Cancer J (2021)

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

بواسطة Chari, Ajai, Cornell, Robert F., Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey V., Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad Z., Anderson, Larry D., Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, Valent, Jason
الحاوية / القاعدة Hematol Oncol (2020)

Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159)

بواسطة Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Anderson, Larry D., Sutherland, Heather J., Yong, Kwee, Hoos, Axel, Gorczyca, Michele M., Lahiri, Soumi, He, Zangdong, Austin, Daren J., Opalinska, Joanna B., Cohen, Adam D.
الحاوية / القاعدة Lancet Oncol (2018)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

بواسطة Dimopoulos, Meletios, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, San-Miguel, Jesus, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Casal, Eva, Srinivasan, Shankar, Yu, Xin, Nguyen, Tuong Vi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
الحاوية / القاعدة Leukemia (2020)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

بواسطة Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
الحاوية / القاعدة Br J Haematol (2018)

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

بواسطة Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.
الحاوية / القاعدة Blood (2020)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

بواسطة Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
الحاوية / القاعدة J Hematol Oncol (2021)